Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141538

Published: 2020

Journal Articles

Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant

Lorenzo Iovino, MD, Sinéad Kinsella, MSc,PhD, Kirsten Cooper, Reema Jain, PhD, Paul DeRoos, Alex Gagnon, Tamas M Ugrai, Gabriele Buda, MD PhD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD, Jarrod A Dudakov, PhD

Blood (2019) 134 (Supplement_1): 4422.

https://doi.org/10.1182/blood-2019-129290

Published: 2019

Journal Articles

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Francesco Mazziotta, MD, Gabriele Buda, MD PhD, Nadia Cecconi, MD, Giulia Cervetti, MD, Lorenzo Iovino, MD, Enrico Orciuolo, MD PhD, Matteo Pelosini, MD PhD, Edoardo Benedetti, MD, Francesco Caracciolo, MD, Giovanni Carulli, MD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD

Blood (2019) 134 (Supplement_1): 3254.

https://doi.org/10.1182/blood-2019-126118

Published: 2019

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Coagulopathy in Patients with Plasmacellular Dyscrasia

Francesca Martini, Gabriele Buda, MD PhD, Nadia Cecconi, Dr, Laura Caponi, Aldo Paolicchi, MD, Mario Petrini, PhD MD Prof

Blood (2017) 130 (Supplement 1): 4867.

https://doi.org/10.1182/blood.V130.Suppl_1.4867.4867

Published: 2017

Journal Articles

Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Gabriele Buda, MD PhD, Rita Fazzi, Giovanni Carulli, MD, Sara Galimberti, MD PhD, Paola Sammuri, Enrico Orciuolo, MD PhD, Iacopo Petrini, Fabrizio Accardi, MD, Laura Notarfranchi, MD, Nicola Giuliani, Mario Petrini

Blood (2016) 128 (22): 5697.

https://doi.org/10.1182/blood.V128.22.5697.5697

Published: 2016

Journal Articles

Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaϊVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study

Lorenzo Iovino, MD, Enrico Orciuolo, MD PhD, Gabriele Buda, MD PhD, Giovanni Carulli, MD, Fabrizio Maggi, Dr, Daniele Focosi, MD, Riccardo Morganti, Dr, Francesca Guerrini, PhD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD

Blood (2016) 128 (22): 1230.

https://doi.org/10.1182/blood.V128.22.1230.1230

Published: 2016

Journal Articles

CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD

Gabriele Buda, MD, Giovanni Carulli, Enrico Orciuolo, Paola Sammuri, Sara Galimberti, MD, Martina Rousseau, MD, Francesca Martini, Mario Petrini

Blood (2015) 126 (23): 1768.

https://doi.org/10.1182/blood.V126.23.1768.1768

Published: 2015

Journal Articles

CD69, a New Potential Clinical Marker in Multiple Myeloma

Gabriele Buda, MD, Giovanni Carulli, Enrico Orciuolo, Paola Sammuri, Daniele Campa, PhD, Sara Galimberti, Mario Petrini, MD

Blood (2014) 124 (21): 2027.

https://doi.org/10.1182/blood.V124.21.2027.2027

Published: 2014

Journal Articles

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Blood (2014) 124 (21): 3421.

https://doi.org/10.1182/blood.V124.21.3421.3421

Published: 2014

Journal Articles

Non Pegylated Liposomal Doxorubicin in Combination with Dexamethasone and Lenalidomide (RMD) Is Active in Advanced MM

Gabriele Buda, MD, Enrico Orciuolo, Martina Rousseau, Sara Galimberti, Nadia Cecconi, Mario Petrini, MD

Blood (2014) 124 (21): 5742.

https://doi.org/10.1182/blood.V124.21.5742.5742

Published: 2014

Journal Articles

Mini-Allogeneic Transplantation in Multiple Myeloma: A Single-Center Ten-Year Experience

Lorenzo Iovino, Enrico Orciuolo, Gabriele Buda, MD, Francesco Caracciolo, Francesco Mazziotta, Sara Galimberti, Mario Petrini, MD PhD, Edoardo Benedetti

Blood (2014) 124 (21): 5928.

https://doi.org/10.1182/blood.V124.21.5928.5928

Published: 2014

Journal Articles

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

Blood (2014) 124 (21): 2044.

https://doi.org/10.1182/blood.V124.21.2044.2044

Published: 2014

Journal Articles

Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias

Blood (2013) 122 (21): 2659.

https://doi.org/10.1182/blood.V122.21.2659.2659

Published: 2013

Journal Articles

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Stefano Sacchi, MD, Samantha Pozzi, MD, Marina Cesaretti, Luigi Marcheselli, MS, Gabriele Buda, MD, Antonio Lazzaro, MD, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, MD, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, MD, Massimo Magagnoli, MD, Franco Silvestris, MD, Pier Paolo Fattori, MD, Patrizia Tosi, MD, Eliana Valentina Liardo, MD, Alessia Bari, MD, Angelo Michele Carella

Blood (2013) 122 (21): 4383.

https://doi.org/10.1182/blood.V122.21.4383.4383

Published: 2013

Journal Articles

VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients

Gabriele Buda, MD, Enrico Orciuolo, Sara Galimberti, Francesco Ghio, Mario Petrini, MD

Blood (2013) 122 (21): 5377.

https://doi.org/10.1182/blood.V122.21.5377.5377

Published: 2013

Journal Articles

Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen.

Enrico Orciuolo, MD, Gabriele Buda, MD, Sara Galimberti, MD, Giuseppe Boni, MD, Nadia Cecconi, MD, Mario Petrini, MD

Blood (2007) 110 (11): 4498.

https://doi.org/10.1182/blood.V110.11.4498.4498

Published: 2007

Journal Articles

Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.

Giovanni Carulli, MD, Sara Galimberti, MD, PhD, Giuseppina Bianchi, Alessandra Zucca, MD, Enrico Orciuolo, MD, Gabriele Buda, MD, Giulia Cervetti, MD, Mario Petrini, MD

Blood (2005) 106 (11): 4670.

https://doi.org/10.1182/blood.V106.11.4670.4670

Published: 2005

NARROW

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Coagulopathy in Patients with Plasmacellular Dyscrasia

Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaϊVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study

CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD

CD69, a New Potential Clinical Marker in Multiple Myeloma

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Non Pegylated Liposomal Doxorubicin in Combination with Dexamethasone and Lenalidomide (RMD) Is Active in Advanced MM

Mini-Allogeneic Transplantation in Multiple Myeloma: A Single-Center Ten-Year Experience

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients

Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen.

Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only